Frequently Asked Questions about Prelude Therapeutics Incorporated (PRLD)

Name: Prelude Therapeutics Incorporated (PRLD) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Prelude Therapeutics Incorporated (PRLD) do?

Accepted Answer

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811...

Question 2

Is Prelude Therapeutics Incorporated (PRLD) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of PRLD reveals an Altman Z-Score of -6.97 and a Piotroski F-Score of 3/9. These metrics, combined with its 5-year revenue trend ($0.01B most recent), help investors decide if PRLD fits their risk profile.

Question 3

What is the current P/E ratio for PRLD?

Accepted Answer

As of the latest trading session, Prelude Therapeutics Incorporated (PRLD) has a trailing P/E ratio of -2.33.

Question 4

Who is the CEO of Prelude Therapeutics Incorporated?

Accepted Answer

The current Chief Executive Officer of Prelude Therapeutics Incorporated is Krishna Vaddi.

Question 5

What was PRLD's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Prelude Therapeutics Incorporated reported annual revenues of $0.01B (2025), $0.01B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does PRLD pay a dividend?

Accepted Answer

Prelude Therapeutics Incorporated does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does PRLD have?

Accepted Answer

In its latest reporting period, Prelude Therapeutics Incorporated generated $-0.06B in Free Cash Flow against a total debt load of $0.02B.

Question 8

What is the Price-to-Book (P/B) ratio of Prelude Therapeutics Incorporated?

Accepted Answer

The Price-to-Book (P/B) ratio for Prelude Therapeutics Incorporated (PRLD) is currently 3.38.

Question 9

What is the Price-to-Sales (P/S) ratio of PRLD?

Accepted Answer

Based on trailing twelve-month data, Prelude Therapeutics Incorporated (PRLD) trades at a Price-to-Sales (P/S) ratio of 16.89.

Question 10

What is Prelude Therapeutics Incorporated's Return on Equity (ROE)?

Accepted Answer

Prelude Therapeutics Incorporated (PRLD) has a Return on Equity (ROE) of -129.98%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	12.1M	10.4M	-104.6M	-99.5M	-1.29
2024-12	7M	7M	-139.7M	-127.2M	-1.68
2023-12	0	0	-132.3M	-121.8M	-2.02
2022-12	0	0	-123.5M	-115.4M	-2.27
2021-12	0	0	-113.7M	-111.7M	-2.33

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	12.1M	10.4M	-104.6M	-99.5M	-1.29
2024-12	7M	7M	-139.7M	-127.2M	-1.68
2023-12	0	0	-132.3M	-121.8M	-2.02
2022-12	0	0	-123.5M	-115.4M	-2.27
2021-12	0	0	-113.7M	-111.7M	-2.33